Product Overview
Composition
Active substance:
fluocinolone acetonide 0.25 mg;
Excipients:
propylene glycol;
citric acid;
lanolin anhydrous;
petroleum jelly white.
pharmachologic effect
Flucinar is a synthetic GCS for external use. It has anti-inflammatory, antipruritic, anti-allergic, anti-exudative action.
The mechanism of anti-inflammatory action is not fully understood. Fluocinolone acetonide inhibits the synthesis of prostaglandins and leukotrienes by inhibiting the activity of phospholipase A2 and reduces the release of arachidonic acid from the phospholipids of the cell membrane. Prevents local allergic reactions in the skin. The antiexudative effect is due to the vasoconstrictor effect.
Pharmacokinetics
Easily penetrates the skin through the stratum corneum. It does not undergo biotransformation in the skin and accumulates in the stratum corneum. Fluociolone acetonide is found in the skin even 15 days after its topical application.
When fluocinolone is used externally, acetonide can be slightly absorbed into the systemic circulation and cause general effects. The absorbed part is biotransformed mainly in the liver and excreted from the body in the form of compounds with glucuronic acid and in a small amount in an unbound form. It is excreted mainly in the urine and slightly in the bile.
The absorption of fluocinolone acetonide is more pronounced when it is applied to the skin of the face and affected areas of the skin, as well as when using occlusive dressings. In addition, the absorption of the drug increases with frequent use and when applied to large areas of the skin. The absorption of the drug in children is more pronounced than in adults.
Flucinar N
Flucinar N is a combination drug with anti-inflammatory and antibacterial action.
Fluocinolone acetonide is a synthetic GCS for external use. It is 40 times more active than hydrocortisone. It has anti-inflammatory, antipruritic, antiexudative, antiallergic and vasoconstrictive effects. The mechanism of anti-inflammatory action has not been fully elucidated. It is believed that fluocinolone acetonide reduces the manifestations of the inflammatory process by inhibiting the synthesis of prostaglandins and leukotrienes by inhibiting the activity of phospholipase A2 and reducing the release of arachidonic acid from the phospholipids of the cell membrane. As a result, hyperemia and exudation in the lesion are reduced. Stabilizes cellular and subcellular (including lysosomal) membranes. Reduces the release of proteolytic enzymes from lysosomes. Reduces membrane permeability, mitotic activity and secretion of inflammation mediators.
When applied to the skin, it prevents marginal accumulation of neutrophils, which leads to a decrease in inflammatory exudate and production of lymphokines, inhibition of macrophage migration, and a decrease in infiltration and granulation processes. It inhibits the alteration phase and limits the inflammation focus, reduces the migration of leukocytes and lymphocytes to the inflammation focus. It inhibits the synthesis or release of cytokines (interleukins and interferon) from lymphocytes and macrophages. Reduces the severity of the early immune response.
Neomycin is an antibiotic of the aminoglycoside group. In low concentrations, it has a bacteriostatic effect, in high concentrations - bactericidal. The mechanism of action is associated with a direct effect on ribosomes and inhibition of bacterial cell protein synthesis.
Flucinar N is active against gram-positive microorganisms: Staphylococcus spp., Streptococcus spp., Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus antracis, Clostridium spp., Actinomyces spp., Neisseria meningitidis; gram-negative microorganisms: Escherichia coli, Shigella spp., Salmonella spp., Proteus spp., Enterobacter aerogenes, Vibrio cholerae, Haemophilus influenzae, Klebsiella pneumoniae, Bordetella pertussis, Pasteurella multocida, Borrelia spp., Treponema pallidum, Fusobacterium spp., Leptospira spp.
It has activity against acid-fast Mycobacterium tuberculosis.
Microorganism resistance to neomycin develops slowly and to a small extent.
As a result of the combined action of fluocinolone acetonide and neomycin, the drug suppresses the development of inflammatory-allergic skin reactions complicated by bacterial infection.
Indications
Acute and severe uninfected, dry inflammatory skin diseases of various origins, accompanied by itching and hyperkeratosis, amenable to GCS treatment:
- seborrheic dermatitis;
- contact eczema;
- atopic dermatitis;
- psoriasis (including psoriasis of the scalp);
- erythematous lichen;
- erythema multiforme;
- lichen planus;
- impetiginous eczema.
Contraindications
- Hypersensitivity;
- acne;
- bacterial (including tuberculosis), fungal, viral and tumor skin diseases.
Side effects
Atrophy of the skin and subcutaneous fat, lupus-like syndrome with a mild course, the appearance or exacerbation of symptoms of lichen planus, epithelialization disorders, delayed healing of wounds and ulcerative lesions, petechiae, steroid purpura, striae, hirsutism, baldness in women, maculopapular skin.
How to take, course of administration and dosage
Apply to the affected surface, rubbing in slightly, 1-2 times a day, no more than 2 g / day. With psoriasis, it is possible to use an occlusive dressing. The duration of the course is no more than 1–2 weeks. Apply on the face skin very carefully and not more than 1 week.
Children over 2 years old - with caution, only once a day, on small areas of the skin.
Overdose
Symptoms: if the dosage regimen is not followed (long-term use of the drug on large areas of the skin), systemic side effects of the drug may develop, such as increased blood pressure, edema, and immunosuppressive effects.
Treatment: drug withdrawal.
Special instructions
Long-term use of the drug Flucinar should be avoided. With prolonged use of GCS on large areas of the skin, the frequency of occurrence of adverse reactions in the form of peripheral edema, arterial hypertension, hyperglycemia, and immunosuppressive action increases.
With the development of a secondary infection at the site of application of the drug Flucinar, antibacterial and antifungal therapy should be prescribed.
With extreme caution, the drug should be used on the skin of the eyelids or in the eye area in patients with glaucoma and cataracts, due to the possible intensification of the symptoms of the disease.
When applied to the skin of the face, the absorption of the drug increases and even after short-term use, the possibility of side effects (telangiectasia, skin atrophy, perioral dermatitis) increases. Use the drug in this area with extreme caution.
Care should be taken to prescribe the drug Flucinar to persons with existing atrophic skin changes, especially to elderly patients.
Release form
Ointment
